Revenue Showdown: Dynavax Technologies Corporation vs Viridian Therapeutics, Inc.

Biotech Revenue Battle: Dynavax vs. Viridian

__timestampDynavax Technologies CorporationViridian Therapeutics, Inc.
Wednesday, January 1, 2014110320004320000
Thursday, January 1, 201540500002538000
Friday, January 1, 2016110430003337000
Sunday, January 1, 20173270004003000
Monday, January 1, 201881980008386000
Tuesday, January 1, 2019352190004461000
Wednesday, January 1, 2020465510001050000
Friday, January 1, 20214394420002963000
Saturday, January 1, 20227226830001772000
Sunday, January 1, 2023232284000314000
Loading chart...

In pursuit of knowledge

Revenue Showdown: Dynavax vs. Viridian

In the ever-evolving landscape of biotechnology, Dynavax Technologies Corporation and Viridian Therapeutics, Inc. have carved distinct paths over the past decade. From 2014 to 2023, Dynavax's revenue trajectory has been nothing short of remarkable, skyrocketing by over 2,000% from its humble beginnings. This surge is largely attributed to their innovative vaccine solutions, which gained significant traction in recent years.

In contrast, Viridian Therapeutics has experienced a more modest revenue journey, with fluctuations reflecting the challenges and opportunities in the therapeutic sector. Despite a peak in 2018, their revenue has seen a decline, highlighting the competitive nature of the industry.

This comparison not only underscores the dynamic nature of biotech revenues but also serves as a testament to the strategic decisions that can propel a company to new heights or present hurdles to overcome.

Published by
U.S. Securities and Exchange Commission

Source link
sec.gov

Date published
17 Jan 2025